KC
ABBV icon

Kinloch Capital’s AbbVie ABBV Stock Holding History

Kinloch Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.42M Buy
24,944
+740
+3% +$164K 2.21% 7
2025
Q4 		$5.53M Sell
24,204
-326
-1% -$74.3K 2.38% 9
2025
Q3 		$5.68M Buy
24,530
+372
+2% +$75.8K 2.48% 5
2025
Q2 		$4.48M Buy
24,158
+833
+4% +$155K 2.09% 8
2025
Q1 		$4.89M Buy
23,325
+4,002
+21% +$778K 2.34% 5
2024
Q4 		$3.43M Buy
19,323
+777
+4% +$143K 1.72% 31
2024
Q3 		$3.66M Sell
18,546
-445
-2% -$83.1K 1.78% 28
2024
Q2 		$3.26M Sell
18,991
-74
-0.4% -$12.3K 1.7% 28
2024
Q1 		$3.47M Buy
19,065
+1,260
+7% +$217K 1.78% 32
2023
Q4 		$2.76M Sell
17,805
-480
-3% -$70K 1.75% 31
2023
Q3 		$2.73M Sell
18,285
-292
-2% -$42.9K 1.71% 32
2023
Q2 		$2.5M Sell
18,577
-301
-2% -$44.1K 1.49% 38
2023
Q1 		$3.01M Sell
18,878
-13,550
-42% -$2.07M 1.76% 32
2022
Q4 		$5.24M Buy
32,428
+914
+3% +$140K 3.05% 4
2022
Q3 		$4.23M Buy
31,514
+209
+0.7% +$30K 2.79% 3
2022
Q2 		$4.79M Buy
31,305
+1,133
+4% +$173K 3.09% 2
2022
Q1 		$4.89M Buy
30,172
+1,196
+4% +$174K 2.93% 3
2021
Q4 		$3.92M Buy
28,976
+7,209
+33% +$852K 2.43% 6
2021
Q3 		$2.35M Buy
21,767
+2,196
+11% +$251K 1.66% 31
2021
Q2 		$2.2M Buy
19,571
+387
+2% +$43.6K 1.58% 34
2021
Q1 		$2.08M Buy
19,184
+1,264
+7% +$135K 1.59% 38
2020
Q4 		$1.92M Buy
+17,920
New +$1.72M 1.62% 34

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kinloch Capital's ABBV Position: Q1 2026 in Review

Kinloch Capital increased its AbbVie (ABBV) stake by 3.1% in Q1 2026, buying an estimated $164K and bringing the position to 24,944 shares worth $5.42M. The position accounts for 2.21% of the portfolio, ranked #7.

Kinloch Capital first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. The position peaked at $5.68M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Kinloch Capital held 24,944 shares of AbbVie worth $5.42M as of Q1 2026.
  • Kinloch Capital bought 740 AbbVie shares in Q1 2026, an estimated $164K.
  • AbbVie made up 2.21% of Kinloch Capital's portfolio in Q1 2026, its #7 holding.
  • Kinloch Capital first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
  • Kinloch Capital's AbbVie position peaked at $5.68M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Kinloch Capital's 13F filing for Q1 2026, filed 15 May 2026.